MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $60.67M (cash outflow) rose 171.6% year over year, ahead of the +146.3% change in trailing-twelve-month net income. Sequentially, it fell 23.7% from the prior quarter. Over 3 fiscal years it compounded at +75.1% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$236.9M (+47.0%) for the fiscal year ending Dec 2026, a slowdown from the +107.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$60.67M-23.7% QoQ
- Last fiscal yearDec 2025
- -$161.15M+107.7% YoY
- LTMMar 2026
- -$199.48M+146.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +171.6% | +101.5% | -70.1 pp |
| 1 year | +107.7% | +47.0% | -60.7 pp |
| 3-year CAGR | +75.1% | +18.0% | -57.1 pp |
| 5-year CAGR | -1.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (161.15M) USD
- Year-over-year change
- -107.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (161.15M) | -107.7% |
| FY2024 | 2024-12-31 | (77.58M) | -39.3% |
| FY2023 | 2023-12-31 | (55.71M) | -85.6% |
| FY2022 | 2022-12-31 | (30.02M) | — |
Net Income vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's LTM Mar 2026 net income of $199.48M is the 4th largest of the 11 companies compared; the peer median is $65.36M.
- Its year-over-year change of +146.3% is the 2nd highest of 9, against a peer median of +25.8%.
- Over three fiscal years its annual growth of +75.1% compares with a peer median of +29.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $108.22B | — | +109.1% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $337.48M | +100.8% | +47.9% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $222.39M | -13.8% | +21.9% | — |
| LTM Mar 2026 | $199.48M | +146.3% | +75.1% | — | |
| LTM Mar 2026 | $122.65M | +233.3% | — | 100.3% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.28M | +34.6% | +118.7% | 536.4% |
| LTM Mar 2026 | $74.31M | +17.6% | +31.7% | — | |
| LTM Mar 2026 | $56.41M | +34.0% | +29.0% | — | |
| LTM Dec 2025 | $39.95M | -14.1% | -1.1% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $39.17M | — | +20.7% | — |
| LTM Mar 2026 | $24.17M | -3.2% | -31.5% | 339.3% | |
| Peer median (excluding MPLT) | $65.36M | +25.8% | +29.0% | 339.3% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Depreciation & Amortization | 574K | 556K | 701K | 578K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.72M | 2.04M | (3.07M) | (12.84M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 |
| Other Working Capital | 1.72M | 2.04M | (3.07M) | (12.84M) |
| Other Non-Cash Items | 1.14M | 1.11M | 1.13M | 35.27M |
| Operating Cash Flow | (26.58M) | (52.01M) | (78.82M) | (138.14M) |
| Capital Expenditures | (746K) | (462K) | (770K) | (473K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (125.02M) | (408.23M) |
| Sales of Investments | 0 | 0 | 45M | 85.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (746K) | (462K) | (80.79M) | (323.21M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 33.17M | 104.57M | 120.25M | 474.84M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 33.18M | 104.57M | (2.19M) | (5.02M) |
| Financing Cash Flow | 33.17M | 104.57M | 118.06M | 469.82M |
| Effect of Forex Changes | 21.81M | 0 | 27K | 0 |
| Net Change in Cash | 27.67M | 52.1M | (41.52M) | 8.48M |
| Free Cash Flow | (27.32M) | (52.47M) | (79.59M) | (138.61M) |
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.